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VRC01-Like Antibodies That Lack Some PVL Characteristic Residues.
Although many VRC01-like antibodies that lack one or more of
the potent VRC01-like (PVL) characteristic residues are clearly
less broad and potent than the main PVL antibodies (Abs), a few
have nearly the same activity. For example, VRC-H5, VRC03
heavy chain paired with the VRC01 light chain, and 12A21 have
very strong neutralization proﬁles (1–3). VRC03HC/VRC01LC and
VRC-H5 lack Trp100BHC. In the crystal structure of VRC03HC/
VRC03LC complexed with gp120 (3), Asn279gp120 is hydrogen
bonded to Asp100CHC, rather than Phe100DHC, the residue that
occupies the usual location for Trp100BHC. Inspection of the
sequence of VRC-H5 in this region suggests that the roles that
Trp100BHC normally plays can instead be performed by a large
hydrophobic residue (e.g., Phe or Leu) at position 100B paired
with a potential hydrogen bond donor or acceptor (e.g., Asn or
Asp) at position 100A. Thus, the characteristic residues we have
identiﬁed are not strictly necessary for potent neutralization. We
suggest, however, that the most common path for Abs to develop
broad VRC01-like activity is by possessing the PVL characteristic
residues.
Polymorphism at 50HC in the Human VH1-2 Gene. The single-
nucleotide polymorphism (SNP) that distinguishes VH1-2 alleles
with Trp50HC (*02, *03, and *04; nucleotide T) from those with
Arg50HC (*01 and *05; nucleotide C) is RefSNP rs1065059
[National Center for Biotechnology Information dbSNP at
www.ncbi.nlm.nih.gov/projects/SNP/]. The minor allele fre-
quency (those alleles encoding Arg50HC) is 23.0% (504 of 1,094
genomes or 2,188 chromosomes). Thus, if the minor allele is
distributed evenly in the population, the fraction homozygous
for the Arg50HC allele is 0.23 × 0.23 = 0.053 = 5.3%.
J Gene Segment Assignment for PVL Abs. Previous analysis of the
D and JH segments used by PVL Abs did not reveal a clear pattern
of J gene segment use (1, 3). For example, VRC01, VRC-PG04,
and VRC-CH31 Abs were reported to use IGHJ1*01, IGHJ2*01,
and IGHJ4*01, respectively (2, 3). However, the relatively high
sequence identity between JH gene segments combined with
the extensive hypermutation of PVL Abs makes the JH gene
assignments uncertain.
One problem with deﬁnitive assignment of JH gene segments in
Abs is that the number of nucleotides assumed to be removed by
exonuclease activity during V-D-J joining can affect the segment
assigned to be the closest match. JoinSolver (4), which uses
a different algorithm from that of ImMunoGeneTics (IMGT)/V-
QUEST (5), assigns IGHJ1*01 for VRC01 partially due to the
assumption that 7 nt were removed from the J gene segment,
whereas the average number of nucleotides removed from the
5′ end of the J segment is 6 (6). Retention of the codon for
Trp100BHC within the JH gene segment requires removal of 4 or
fewer nt. Examination of a set of human Abs derived from
IGHJ2*01 suggests that retention of these nucleotides is not
uncommon (e.g., retention occurs in 7 of 10 of the IGHJ2*01-
containing Abs included in a previous study) (7).
To further explore the J gene segment assignment by IMGT/V-
QUEST, we attempted to remove any bias caused by inclusion of
the Trp100BHC. Even if the Trp100BHC codon is changed to
CCT, a codon not found in any JH gene segment at that position,
VRC-PG04 and 3BNC117 are still predicted by IMGT/V-QUEST
to derive from IGHJ2*01, whereas VRC01 and 12A12 are then
predicted to derive from IGHJ1*01 and IGHJ4*02, respectively.
Sequence Features That Vary Among PVL Abs, Including Insertions,
Deletions, and Variations Within the CDRs.Although PVL Abs share
common features, other aspects of these Abs vary considerably.
For example, the CDRH1 length varies between 10 in many
PVLs; 11 in VRC-PG04, VRC-H12, VRC-H15; and 19 in VRC-
CH31 and related clones (1–3). For PVLs VRC01 and NIH45–46,
CDRH1 disulﬁde bonds with CDRH3. Although Trp100BHC near
the C-terminal end of CDRH3 is common to PVL Abs, the pre-
ceding portion of CDRH3 is highly variable. For some PVL Abs,
this region of CDRH3 may contact the inner domain of gp120, as
observed for NIH45–46 (8), whereas the shorter VRC01 CDRH3
does not.
In the light chain, the CDRL1 length is quite variable: 7 in the
3BNC clones; 9 in VRC01, NIH45–46, and VRC-PG04; and 11 in
12A12 and the VRC-CH31–related clones (1–3). The shorter
versions are deletions from the germ line.
Several insertions also occur in PVL Abs. In VRC03, in
framework region 3 (after Arg71HC) there is a seven-residue
insertion. In 3BNC60 and related potent clonal variants, there is
a four-residue insertion (sequence WDFD) in apparently the
same location. When these Abs are complexed with gp120, these
insertions are predicted to contact the V1V2 base in the bridging
sheet (1).
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Fig. S1. Sequence alignment of CD4 binding site Abs. (A) Sequence alignment of highly active agonistic anti-CD4bs (HAAD) heavy chains, precursor
germ-line V gene segments (Upper), and the 8ANC195 heavy chain (1). Characteristic PVL residues are highlighted in purple. (B) Sequence alignment of HAAD
and 8ANC195 light chains (1). Characteristic PVL residues are highlighted in purple.
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Fig. S2. Fraction of residues changed from germ line in a set of 253 VH1-2*02–derived Abs. Characteristic PVL residues are shown in purple. CDRH1 and
H2 (a contact-based deﬁnition as deﬁned by ref. 1) are shown in red.
Fig. S3. Stereo depiction of the NIH45–46/gp120 complex highlighting the common interactions of PVL Abs (heavy chain in magenta and light chain in cyan)
with gp120 (black). The perspective is the same as used in the schematic illustration in Fig. 3.
1. MacCallum RM, Martin AC, Thornton JM (1996) Antibody-antigen interactions: Contact analysis and binding site topography. J Mol Biol 262:732–745.
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Fig. S4. Sequence of the 3BNC60 germ-line heavy chain used in the surface plasmon resonance binding experiment shown in Fig. 4. The underlined sections
match VH1-2*02 and IGHJ2*01. The red section (mainly the D gene segment and added nucleotides) matches the mature 3BNC60 heavy chain. Point mutants
were made at the residues shown in blue. The germ-line construct is also shown aligned with the mature 3BNC60 heavy chain.
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Fig. S5. Alignment of PVL heavy-chain sequences with IGHV1 gene segments. PVL characteristic residues are highlighted in purple. Germ-line segments
indicated with “#” have PVL characteristic residues Trp50HC, Asn58HC, and Arg71HC.
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Fig. S6. Sequences of envelopes from donor 45 and four other individuals as reported in ref. 1. Sequences for residues 269–285 and 449–471 are shown; strains
are listed in order of their VRC01 IC50. Residues 279, 280, and 456–459 are highlighted.
1. Wu X, et al. (2012) Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol 86:5844–5856.
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Table S1. Classiﬁcation of CD4-binding site Abs
Class Members
PVL Abs, neutralizing >75% of strains VRC01, VRC02
NIH45–46
3BNC60, 3BNC117, 3BNC62, 3BNC95, 3BNC176
12A12
VRC-PG04
VRC-CH31, VRC-CH30, VRC-CH32, VRC-CH33, VRC-CH34
VRC03HC/VRC01LC
gVRC-H5(d74)/VRC-PG04LC gVRC-H12(d74)/VRC-PG04LC*
Almost PVL Abs, related to known
PVL Abs, neutralizing 10–75% of strains
VRC03
VRC01HC/VRC03LC
3BNC55, 3BNC91, 3BNC104, 3BNC89
12A21
VRC-PG04b
Defective PVL Abs, related to known
PVL Abs, neutralizing <10% of strains
3BNC42, 3BNC53, 3BNC66, 3BNC72, 3BNC102
3BNC108, 3BNC142, 3BNC153, 3BNC156, 3BNC158
Germ-line parents of PVL Abs
Non-PVL HAADs 8ANC131
8ANC134
1B2530
1NC9
And related clones
Other CD4-binding site Abs HJ16†
b12
b13
F105
8ANC195
Antibodies are described in refs. 1–4.
*Plus seven additional HC clones (paired with PG04 LC) from deep sequencing of donor 74.
†HJ16 sequences (patent WO2011092593) do not appear to be particularly similar to PVLs. CDRL3 is 9 aa long,
the heavy chain does not derive from VH1-2, and the Ab is missing several of the signature PVL residues.
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Table S3. HIV-1 strains with sequence variations at critical PVL contact residues: Analysis based
on NIH45–46 data as described in ref. 1
Critical contact residues on gp120 IC50, μg/mL
Strain 279 280 456 458 459 VRC01 NIH45–46 VRC-PG04 3BNC117
Residue in most
PVL-sensitive
strains
Asx Asn Arg Gly Gly
620345_c1 Lys Ser Asp >50 >50 >50 >15
89_F1_2_25 Ser Asn ND >50 ND >50
6540_v4_c1 Ser Ser Tyr >50 >50 >50 >50
6545_v4_c1 Ser Ser Tyr >50 >50 ND >50
Du422.1 Trp >50 >50 >50 >50
T250_4 Pro >50 >50 >50 >15
T278_50 Ala Glu >50 >50 >50 >15
Ce1172_H1 −/Ile ND >50 ND >50
X2088_c9 Val >50 >50 >50 >50
H086.8 Lys Asp >50 >30 >50 >15
Neutralization data are from refs. 2–4. Position 279gp120 was previously shown to be important in resistance
to VRC01; speciﬁcally the effects of mutation D279Agp120 in JRCSF, T278_50, BL01, and TV1_29 viral strains were
evaluated (5).
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Table S2. Cross-species analysis for the presence of PVL
characteristic residues in heavy-chain V gene segments
Species
No. VHs
examined
No. w/W50
and R71
No. w/W50, N58,
and R71
Human 70 7* 4†
Mouse 269 0 0
Rat 204 1‡ 0
Rabbit 49 2§ 0
Sheep 10 0 0
Pig 5 0 0
Rhesus macaque 89 1{ 0
VH gene segment sequences from the IMGT database were examined,
except for the macaque sequences, which were obtained from the Rhesus
macaque Ig gene database (http://www.kcl.ac.uk/immunobiology/Mac_ig/).
For the human genes, all VH alleles in IMGT were also checked.
*VH1-2*02, VH1-45*01, VH1-58*01, VH1-68*01, VH1-c*01, VH1-3*01, and
VH1-8*01.
†VH1-2*02, VH1-45*01, VH1-58*01, and VH1-68*01 (pseudogene).
‡IGHV12S1*01.
§IGHV1S55*01 and IGHV1S56*01.
{IGHV1l.
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